RPG Life Sciences Subsidiary RPG Active Pharma Approves Merger Of Actis Generics

Market snapshot: RPG Life Sciences Limited's wholly owned subsidiary, RPG Active Pharma Limited, has approved a scheme of amalgamation to merge its wholly owned subsidiary, Actis Generics Private Limited, with itself. The corporate restructuring, approved by the board on September 25, 2026, aims to consolidate assets, streamline operations, and eliminate duplicate administrative costs.

Data Snapshot

• Actis Generics recorded standalone revenue from operations of ₹45.96 crore for the financial year ended March 31, 2026.
• RPG Active Pharma, incorporated on December 24, 2025, recorded a net worth of ₹34.75 crore with zero operational revenue as of March 31, 2026.
• RPG Life Sciences posted standalone Q1 FY27 revenue from operations of ₹195.7 crore, representing a 15.8% year-on-year growth.

What's Changed

• RPG Life Sciences standalone revenue increased 15.8% YoY to ₹195.7 crore in Q1 FY27 from ₹168.9 crore in Q1 FY26.
• EBITDA grew 17.9% YoY to ₹48 crore in Q1 FY27 from ₹40.7 crore in Q1 FY26, expanding the EBITDA margin to 24.5%.

Key Takeaways

• Amalgamation of Actis Generics into transferee RPG Active Pharma consolidates resources, eliminating administrative duplications and legal entity layers.
• As Actis Generics is already a wholly owned subsidiary of RPG Active Pharma, the transaction proceeds without share issuance or cash outflow, maintaining the existing equity structure.
• The transaction brings Actis's API intermediate strengths directly into RPG Active Pharma, strengthening the platform’s manufacturing base and synergies.
• The amalgamation scheme remains subject to necessary statutory approvals, including consent from shareholders and the National Company Law Tribunal (NCLT).

SAHI Perspective

This internal restructuring represents a logical next step following RPG Active Pharma's acquisition of Actis Generics. Rather than maintaining multiple corporate entities with separate administrative structures, merging Actis into RPG Active Pharma simplifies governance and enhances cost competitiveness. By housing the assets under a single operational roof, the group can better utilize the ₹243 crore private equity funding from InvAscent to scale up its broader API play, which now includes both Actis Generics and the recently acquired API business of Raghava Life Sciences.

Market Implications

By streamlining its corporate structure, RPG Life Sciences improves its operational efficiency and margins. Housing all API operations under one subsidiary—RPG Active Pharma—makes the unit a cleaner, more attractive platform for future capital allocation and external partnerships. It also enables RPG Life Sciences to present a clear formulations-led focus on its standalone books while building a scaled, independent API platform under RPG Active Pharma.

Trading Signals

Market Bias: Bullish

The consolidation of Actis Generics into RPG Active Pharma removes duplicate expenses and simplifies corporate structure, building on the company's strong Q1 FY27 operational performance where revenue rose 15.8% to ₹195.7 crore.

Overweight: Healthcare, Pharmaceuticals

Trigger Factors:

• Statutory and NCLT clearance of the amalgamation scheme.
• Integration of Actis Generics' intermediate manufacturing with RPGAP's API platform.
• Commercialization and capacity utilization ramp-up of newly acquired API assets.

Time Horizon: Medium-term (3-12 months)

Industry Context

The global pharmaceutical supply chain is undergoing a structural shift, with drugmakers actively looking to diversify and reduce their dependence on single-source suppliers for Active Pharmaceutical Ingredients (APIs). RPG Life Sciences' consolidation strategy, funded by private equity partners like InvAscent, aligns with this trend. By integrating intermediates capability from Actis and scaling up manufacturing through acquisitions (such as Raghava Life Sciences' 300 KL facility near Hyderabad), the company is preparing to capture higher export volumes in highly regulated markets.

Key Risks to Watch

• Delays in integrating physical assets, R&D pipelines, and teams across newly acquired entities could hinder projected cost-saving synergies.
• The merger is subject to NCLT and shareholder approvals, and any procedural delay could extend the transaction timeline.
• Price fluctuations in bulk drugs or input raw materials could put pressure on near-term operating margins of the newly consolidated entity.

Recent Developments

RPG Active Pharma completed the acquisition of Actis Generics on September 24, 2026. Additionally, it executed a business transfer agreement to acquire Raghava Life Sciences' API business for up to ₹135 crore, which became effective on September 16, 2026. These transactions are partly funded by a ₹243 crore equity infusion from private equity firm InvAscent.

Closing Insight

This amalgamation is a clear indicator of disciplined corporate hygiene. Rather than letting acquired entities operate in silos, RPG Life Sciences is proactively folding them into a unified operational vehicle. This clean structure will maximize the synergistic benefits of its recent acquisitions and pave the way for a more robust, integrated API growth engine.

High Performance Trading with SAHI.